Published in the Journal of Rehabilitation and Assistive Technologies Engineering (RATE), the study
further supports coding of devices based on patient outcomes instead of mechanical features
AUSTIN, Texas, June 24, 2022 – Hanger, Inc. today announced results of its Outcomes
ASsessment and DISsemination (OASIS) II study, which evaluates
the effectiveness of 10 common prosthetic feet models across L5981 and L5987 procedure codes, as assigned by the
Centers for Medicare & Medicaid Services (CMS)’s Pricing, Data, Analysis and Coding (PDAC) contractor for
orthotic and prosthetic devices. The second study in the OASIS series by the Hanger Institute for
Clinical Research and Education reports L5987-coded feet are associated with improved mobility
compared to the L5981 category, a confirmation of results reported previously in a purely dysvascular/diabetic
population of 738 individuals with amputation in the Institute’s Mobility Analysis of Amputees
(MAAT) 5 study. The latest study also questions whether prosthetic feet and componentry should be
categorized based on functional outcomes instead of mechanical features.
“At Hanger, we believe our clinical care should be measured by the outcomes we achieve, not the devices we
deliver,” shared James Campbell, PhD, Hanger Chief Clinical Officer. “This second OASIS study uses real-world
clinical outcomes data to demonstrate that emphasizing functional performance over visible characteristics may be a
pathway toward higher performance for the end user.”
The OASIS II study was designed to investigate real-world evidence on several highly utilized prosthetic
feet that were re-coded from L5987 to L5981 due to a lack of visual distinct vertical loading mechanism. The
analysis compared functional outcomes of 526 users across a variety of etiologies who utilized prosthetic feet that
retained an L5987 coding, prosthetic feet that were newly assigned an L5981 coding, and those that sustained an
L5981 coding. Results showed no significant difference in functional mobility for individuals with prosthetic feet
that had its coding modified to L5981, compared to those that retained the L5987 designation.
“As the leading independent provider of orthotic and prosthetic care in the nation, Hanger remains
uniquely positioned to collect outcomes data and quantify performance associated with different manufacturing
components,” stated Hanger President and Chief Executive Officer Vinit Asar. “Having the ability to objectively
measure, analyze, and disseminate real-world functional outcomes enables clinical providers to make informed,
unbiased decisions about patient care, resulting in enhanced outcomes.”
The OASIS series is part of a vast collection of landmark research studies already published, or in
various stages of publication by the Hanger Institute for Clinical Research and Education, in collaboration with
leading researchers, clinical, and academic institutions. Additional information on OASIS II and previously
published research can be found here: https://hangerclinic.com/for-professionals/research-innovation/.
About Hanger, Inc. – Headquartered in Austin, Texas, Hanger, Inc. (NYSE: HNGR) provides
comprehensive, outcomes-based orthotic and prosthetic (O&P) services through its Patient Care segment, with
approximately 875 Hanger Clinic locations nationwide. Through its Products & Services segment, Hanger
distributes branded and private label O&P devices, products and components, and provides rehabilitative
solutions. Recognized by Forbes as one of America’s Best Employers for 2022, and rooted in 160 years of
clinical excellence and innovation, Hanger is a purpose-driven company with a vision to lead the O&P markets by
providing superior patient care, outcomes, services and value, aimed at empowering human potential. For more
information on Hanger, visit corporate.hanger.com.
###
Krisita Burket, Hanger, Inc.
904-239-4627, kburket@hanger.com
Meghan Williams, Hanger, Inc.
512-777-3701, megwilliams@hanger.com